IMC Presentation on Company Website

Physiomics PLC

02 February 2024

 

2 February 2024

RNS Reach

Physiomics plc

("Physiomics" or "the Company")

IMC Presentation on Company Website

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, recently provided a brief update on the Board changes via Investor Meet Company and has updated its website with the presentation.

The presentation and Q&A from the meeting are now available at the Company's website:

www.physiomics.co.uk/portfolio-item/investor-presentation-board-changes

Enquiries:

Physiomics plc

Dr Jim Millen, Non-Executive Chairman, [phone]

Dr Peter Sargent, Chief Executive Officer, [phone]

Hybridan LLP (Broker)

Claire Louise Noyce

[phone]

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

[phone]

Notes to Editor

About Physiomics

Physiomics plc combines cutting edge PKPD and QSP modelling and data science techniques, along with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design research across discovery, pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

 

END